Skip to main content

Research Repository

Advanced Search

All Outputs (10)

Feasibility of whole-body MRI for cancer screening in children and young people with Ataxia Telangiectasia: a mixed methods cross-sectional study (2024)
Journal Article
Neves, R., Panek, R., Wilne, S., Suri, M., Whitehouse, W., Dandapani, M., Glazebrook, C., & Dineen, R. (2024). Feasibility of whole-body MRI for cancer screening in children and young people with Ataxia Telangiectasia: a mixed methods cross-sectional study. Cancer Medicine, 13(14), Article e70049. https://doi.org/10.1002/cam4.70049

Background/Objectives: Ataxia telangiectasia (A‐T) is an inherited multisystem disorder with increased sensitivity to ionising radiation and elevated cancer risk. Although other cancer predisposition syndromes have established cancer screening protoc... Read More about Feasibility of whole-body MRI for cancer screening in children and young people with Ataxia Telangiectasia: a mixed methods cross-sectional study.

The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review (2024)
Journal Article
Wilson, J. S., Main, C., Thorp, N., Taylor, R. E., Majothi, S., Kearns, P. R., …Pizer, B. (2024). The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review. Journal of Neuro-Oncology, 167(1), 1-34. https://doi.org/10.1007/s11060-023-04510-4

Background Central nervous system (CNS) tumours account for around 25% of childhood neoplasms. With multi-modal therapy, 5-year survival is at around 75% in the UK. Conventional photon radiotherapy has made significant contributions to survival, but... Read More about The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review.

Understanding recent advances in genomic testing in paediatric oncology (2023)
Journal Article
Robinson, S. L., Seneviratne, N., & Dandapani, M. (2024). Understanding recent advances in genomic testing in paediatric oncology. Paediatrics and Child Health, 34(2), 43-48. https://doi.org/10.1016/j.paed.2023.11.001

Advancements in genomics have had a significant impact on our ability to diagnose and treat several health conditions, notably cancer. In this article, we discuss the evolution of genomic methods from the early first-generation genome sequencing meth... Read More about Understanding recent advances in genomic testing in paediatric oncology.

Development of cancer surveillance guidelines in ataxia telangiectasia: A Delphi‐based consensus survey of international experts (2023)
Journal Article
Neves, R., DeDiosPerez, B., Panek, R., Jagani, S., Wilne, S., Mahendra Bhatt, J., …Dineen, R. A. (2023). Development of cancer surveillance guidelines in ataxia telangiectasia: A Delphi‐based consensus survey of international experts. Cancer Medicine, 12(13), 14663-14673. https://doi.org/10.1002/cam4.6075

Background/Objectives: Ataxia telangiectasia (A‐T) is a multiorgan disorder with increased vulnerability to cancer. Despite this increased cancer risk, there are no widely accepted guidelines for cancer surveillance in people affected by A‐T. We aime... Read More about Development of cancer surveillance guidelines in ataxia telangiectasia: A Delphi‐based consensus survey of international experts.

Whole-body MRI for cancer surveillance in ataxia–telangiectasia: A qualitative study of the perspectives of people affected by A-T and their families (2023)
Journal Article
Neves, R., Perez, B. D. D., Tindall, T., Fernandez, N. S., Panek, R., Wilne, S., …Glazebrook, C. (2023). Whole-body MRI for cancer surveillance in ataxia–telangiectasia: A qualitative study of the perspectives of people affected by A-T and their families. Health Expectations, 26(3), 1358-1367. https://doi.org/10.1111/hex.13756

Background/Objectives: Ataxia–telangiectasia (A-T) is a complex inherited disease associated with an increased risk of malignancy. Surveillance guidelines have demonstrated significant health benefits in other cancer predisposition syndromes. However... Read More about Whole-body MRI for cancer surveillance in ataxia–telangiectasia: A qualitative study of the perspectives of people affected by A-T and their families.

EPCT-03. Working together to accelerate the preclinical to clinical translation of drug delivery systems for children’s brain tumours (2022)
Presentation / Conference Contribution
Campbell, E., Aquilina, K., Dandapani, M., Walker, D., & Rahman, R. (2022). EPCT-03. Working together to accelerate the preclinical to clinical translation of drug delivery systems for children’s brain tumours. Neuro-Oncology, 24(Supplement 1), i36-i36. https://doi.org/10.1093/neuonc/noac079.131

Children's brain tumours are the biggest cancer killer in children and young adults. Several techniques, such as intra-cerebrospinal fluid chemotherapy, ultrasound-mediated blood-brain barrier disruption, convection enhanced delivery, polymer deliver... Read More about EPCT-03. Working together to accelerate the preclinical to clinical translation of drug delivery systems for children’s brain tumours.

TBIO-14. Characterisation of the arginine pathway enzymes in paediatric brain tumours to determine susceptibility to therapeutic arginine depletion (2020)
Presentation / Conference Contribution
Bishop, E., Dimitrova, M., Storer, L., Grundy, R., & Dandapani, M. (2020). TBIO-14. Characterisation of the arginine pathway enzymes in paediatric brain tumours to determine susceptibility to therapeutic arginine depletion. Neuro-Oncology, 22(Issue Supplement_3), iii469. https://doi.org/10.1093/neuonc/noaa222.841

INTRODUCTION Extracellular arginine dependency (auxotrophy) is increasingly being recognised in several tumours. This is due to the inability of cancer cells to recycle or synthesise intracellular arginine through the urea cycle pathway compared to... Read More about TBIO-14. Characterisation of the arginine pathway enzymes in paediatric brain tumours to determine susceptibility to therapeutic arginine depletion.

AMP-Activated Protein Kinase: Friend or Foe in Cancer? (2019)
Journal Article
Vara-Ciruelos, D., Dandapani, M., & Hardie, D. G. (2020). AMP-Activated Protein Kinase: Friend or Foe in Cancer?. Annual Review of Cancer Biology, 4(1), 1-16. https://doi.org/10.1146/annurev-cancerbio-030419-033619

The AMP-activated protein kinase (AMPK) is activated by energy stress and restores homeostasis by switching on catabolism, while switching off cell growth and proliferation. Findings that AMPK acts downstream of the tumor suppressor LKB1 have suggest... Read More about AMP-Activated Protein Kinase: Friend or Foe in Cancer?.

Phenformin, But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia/Lymphoma via Cell-Autonomous AMPK Activation (2019)
Journal Article
Vara-Ciruelos, D., Dandapani, M., Russell, F. M., Grzes, K. M., Atrih, A., Foretz, M., …Hardie, D. G. (2019). Phenformin, But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia/Lymphoma via Cell-Autonomous AMPK Activation. Cell Reports, 27(3), 690-698.e4. https://doi.org/10.1016/j.celrep.2019.03.067

AMPK acts downstream of the tumor suppressor LKB1, yet its role in cancer has been controversial. AMPK is activated by biguanides, such as metformin and phenformin, and metformin use in diabetics has been associated with reduced cancer risk. However... Read More about Phenformin, But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia/Lymphoma via Cell-Autonomous AMPK Activation.

Genotoxic Damage Activates the AMPK-α1 Isoform in the Nucleus via Ca2þ/CaMKK2 Signaling to Enhance Tumor Cell Survival (2017)
Journal Article
Vara-Ciruelos, D., Dandapani, M., Gray, A., Egbani, E. O., Evans, A. M., & Hardie, D. G. (2018). Genotoxic Damage Activates the AMPK-α1 Isoform in the Nucleus via Ca2þ/CaMKK2 Signaling to Enhance Tumor Cell Survival. Molecular Cancer Research, 16(2), 345-357. https://doi.org/10.1158/1541-7786.mcr-17-0323

2017 American Association for Cancer Research. Many genotoxic cancer treatments activate AMP-activated protein kinase (AMPK), but the mechanisms of AMPK activation in response to DNA damage, and its downstream consequences, have been unclear. In this... Read More about Genotoxic Damage Activates the AMPK-α1 Isoform in the Nucleus via Ca2þ/CaMKK2 Signaling to Enhance Tumor Cell Survival.